SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: seminole who wrote (5539)1/24/2002 6:15:36 PM
From: Biomaven  Read Replies (1) | Respond to of 52153
 
Hi Richard -

Any news from the front? I still have some MOGN shares from way back, but haven't kept track of the Yahoo board. The stock has been doing pretty well.

The pancreatic Ph III should conclude this year, right?

I've always believed Irofulven is going to be an approvable drug. I think Miljenko has always disagreed with me on this one. <g>

You have any comment on MOGN's methyltransferase stuff? I realize you may not be able to comment much on Irofulven.

Peter



To: seminole who wrote (5539)1/24/2002 11:23:17 PM
From: Miljenko Zuanic  Read Replies (2) | Respond to of 52153
 
Richard,

For your benefit (and Peter, and all MOGN SH) I hope that you are/were correct and I am/was wrong. Most my hope is for those who suffer from cancer and Iro may be new opportunity to fight.

I did not follow closely IRO time frame and new development lately. Will do it one day. For now, I will continue to be cautious. Have now idea am asking stupid question, but at what point MOGN will consider EU, and to follow US marketing partner?

Miljenko


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News